Leerink Swann reaffirmed their outperform rating on shares of Incyte Corp. (NASDAQ:INCY) in a research report sent to investors on Sunday. The brokerage currently has a $115.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $101.00.

A number of other research firms have also recently commented on INCY. BMO Capital Markets reaffirmed an outperform rating and set a $126.00 price objective (up from $121.00) on shares of Incyte Corp. in a research report on Saturday. RBC Capital Markets reaffirmed an outperform rating and set a $116.00 price objective on shares of Incyte Corp. in a research report on Monday, October 10th. JMP Securities lifted their price objective on shares of Incyte Corp. from $100.00 to $110.00 and gave the stock a market outperform rating in a research report on Monday, October 10th. Zacks Investment Research raised shares of Incyte Corp. from a hold rating to a buy rating and set a $107.00 price objective for the company in a research report on Tuesday, October 4th. Finally, Piper Jaffray Cos. set a $99.00 target price on Incyte Corp. and gave the stock a buy rating in a report on Wednesday, September 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $103.08.

Analyst Recommendations for Incyte Corp. (NASDAQ:INCY)

Incyte Corp. (NASDAQ:INCY) traded down 1.82% during midday trading on Friday, hitting $103.63. 1,103,094 shares of the stock traded hands. The firm’s 50 day moving average is $92.87 and its 200-day moving average is $84.56. The stock has a market capitalization of $19.52 billion, a PE ratio of 139.29 and a beta of 0.79. Incyte Corp. has a 12-month low of $55.00 and a 12-month high of $118.49.

In related news, EVP Paula J. Swain sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, October 20th. The stock was sold at an average price of $90.00, for a total value of $900,000.00. Following the sale, the executive vice president now directly owns 39,248 shares in the company, valued at $3,532,320. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paula J. Swain sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, September 23rd. The shares were sold at an average price of $90.00, for a total value of $1,800,000.00. Following the completion of the sale, the executive vice president now owns 49,248 shares in the company, valued at $4,432,320. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in INCY. D.A. Davidson & CO. boosted its stake in shares of Incyte Corp. by 43.1% in the third quarter. D.A. Davidson & CO. now owns 9,368 shares of the biopharmaceutical company’s stock valued at $881,000 after buying an additional 2,822 shares during the last quarter. Credit Suisse AG boosted its stake in shares of Incyte Corp. by 8.5% in the third quarter. Credit Suisse AG now owns 539,824 shares of the biopharmaceutical company’s stock valued at $50,900,000 after buying an additional 42,438 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Incyte Corp. by 2.0% in the third quarter. Ameritas Investment Partners Inc. now owns 3,376 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 65 shares during the last quarter. Pioneer Investment Management Inc. bought a new stake in shares of Incyte Corp. during the third quarter valued at approximately $7,621,000. Finally, Chartwell Investment Partners LLC bought a new stake in shares of Incyte Corp. during the third quarter valued at approximately $8,284,000. Institutional investors and hedge funds own 92.14% of the company’s stock.

Incyte Corp. Company Profile

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.